Tailored treatment with targeted therapies in non-small cell lung cancer (NSCLC) based on the epidermal growth factor receptor gene (EGFR) mutation testing.

e19150 Background: About 10-20% of NSCLC tumors harbor activating EGFR mutations. The introduction of new therapies targeting EGFR has achieved a significant impact on survival and their use has replaced standard chemotherapy in patients (p) with EGFR-mutated NSCLC. Methods: Epidemiological, descriptive, case-control study in p attended in the Medical Oncology Department of the Hospital Universitario de Gran Canaria Dr Negrin (Canary Islands, Spain) diagnosed with advanced NSCLC between 2010 and 2012. We analyzed p tested for EGFR mutations during the treatment decision process. Results: Overall population (Table): 104 p [64 males, 40 females, mean age 59 years (range 36-83), 77.8% adenocarcinoma]. As of January 2014, 21 p were alive (16 on treatment, 5 without treatment) and 83 were dead (96.2% due to disease progression). Overall survival (OS) was 8 months (m) (95% CI 5.8-10.1). OS for p treated vs not treated was 11 and 2 m respectively (p<0.0001). Mutated population: 20 p (19.2%) presented tumors harb...